ReviewStem cell reviews and reports2026
Unlocking Alveolar Regeneration: AT2 Stem Cells, Signaling Networks, and Therapeutic Frontiers.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This review elucidates the pivotal role of alveolar type II epithelial cells (AT2) as key adult stem cells in lung homeostasis maintenance and post-injury repair, with molecular regulatory mechanisms. We synthesize current knowledge on AT2 self-renewal and differentiation into alveolar type I epithelial cells (AT1), and how their dysfunction drives refractory lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. By evaluating findings from lineage tracing, single-cell transcriptomics, and three-dimensional organoid culture, this article outlines the cellular atlas of alveolar regeneration. This atlas encompasses not only AT2 cells and alveolar epithelial progenitors, but also auxiliary progenitor sources such as bronchioalveolar stem cells and lineage-negative epithelial progenitors. Notably, the review highlights the transitional plasticity stage—alveolar differentiation intermediate states—during AT2-to-AT1 differentiation. Mechanistically, the review delves into the intricate signaling networks governing AT2 cell fate, including key pathways such as Wnt/β-catenin, Hippo-YAP, Notch, and BMP. Crucially, it emphasizes that AT2 cell regenerative capacity relies on a multilayered quality control system involving epigenetic regulation, metabolic reprogramming, organelle homeostasis, and telomere maintenance. Furthermore, mesenchymal and immune cells within the alveolar stem cell niche engage in precise paracrine crosstalk with AT2 cells to collectively orchestrate regeneration. Finally, this review bridges fundamental biological discoveries with clinical prospects, illustrating how AT2 cells may serve as biomarkers for disease diagnosis, vehicles for gene-targeted therapy, and sources for cell replacement therapy. It outlooks novel treatments by modulating AT2 stem cell function—including small-molecule drugs, gene-editing nanoplatforms, and stem cell transplantation—heralding a transformative era in pulmonary regenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.